Protein Kinase RNA Like Endoplasmic Reticulum Kinase Mediated Bcl 2 Protein Phosphorylation Contributes to Evodiamine Induced Apoptosis of Human Renal Cell Carcinoma Cells
We investigated the anticancer mechanism of evodiamine (EVO) against the viability of human A498 renal cell carcinoma (RCC) cells in vitro and in vivo. The in vitro study showed that EVO decreased the viability of A498 cells with the occurrence of apoptotic characteristics such as hypodiploid cells, DNA ladders, chromatin condensed cells, and cleaved caspase (Casp) 3/poly(ADP ribose) polymerase (PARP) proteins. Pharmacological studies using chemical inhibitors of mitogen activated protein kinase (MAPK) and phosphoinositide 3 kinase (PI3K) indicated that phosphorylation of the c Jun N terminal kinase (JNK) protein participated in EVO induced cell death of A498 cells, and application of the JNK inhibitor, SP600125 (SP) inhibited EVO induced cleavage of the Casp 3/PARP proteins and chromatin condensation according to Giemsa staining. EVO disruption of the mitochondrial membrane potential (MMP) with increased protein levels of the phosphorylated Bcl 2 protein (p Bcl 2) was prevented by JNK inhibitors in A498 cells. A structure activity relationship study showed that a methyl group at position 14 in EVO was important for its apoptotic effects and increased p Bcl 2 protein in A498 cells. Furthermore, significant increases in the phosphorylated endoplasmic reticular stress protein, protein kinase RNA like endoplasmic reticulum kinase (p PERK at Thr980) by EVO were detected in A498 cells, and the PERK inhibitor, GSK2606414, significantly suppressed EVO induced apoptosis, p JNK, p PERK, and cleaved PARP proteins. The in vivo study showed that EVO significantly reduced RCC growth elicited by a subcutaneous injection of A498 cells, and an increased protein level of p PERK was observed according to an immunohistochemical analysis. Apoptosis by EVO was also demonstrated in other RCC cells such as 786 O, ACHN, and Caki 1 cells. This is the first study to demonstrate the anti RCC effect of EVO via apoptosis in vitro and in vivo, and activation of JNK and PERK to induce Bcl 2 protein phosphorylation, which led to disruption of the MMP.
PloS one